The anti-tumor agent, p-DDAP potently suppresses proliferation through apoptosis in human neuroblastoma NB-39-nu cells.

Abstract

Retinoic acid (RA) is a chemotherapeutic agent used to induce neuronal cellular differentiation of neuroblastoma. However, because treatment with RA is associated with the side-effect of nyctalopia, efforts have been underway to identify new compounds that could potentially overcome these drawbacks. As part of these studies we have examined anti-cancer effects on the neuroblastoma NB-39-nu cells of p-dodecylaminophenol (p-DDAP), a novel derivative of N-(4-hydroxyphenyl) retinamide (4-HPR). p-DDAP suppresses proliferation, and induces G(0)/G(1) arrest and apoptosis to a greater extent than RA and 4-HPR. Neuronal differentiation was not detected in p-DDAP-treated cells. Since p-DDAP is not toxic and does not reduce blood retinol levels, p-DDAP might be a useful anti-neuroblastoma drug having reduced side-effects.

• Authors: Noriko Takahashi, Rumi Egawa, Masahiko Imai, Katsuhiko Takahashi, Toshihiro Ohba, Masue Imaizumi
• Journal: Cancer letters (Cancer Lett) Vol. 297 Issue 2 Pg. 252-8 (Nov 28 2010) ISSN: 1872-7980 [Electronic] Ireland
• PMID: 20580487 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Aminophenols
• Antineoplastic Agents

Topics

• Aminophenols (pharmacology)
• Antineoplastic Agents (pharmacology)
• Apoptosis (drug effects)
• Cell Cycle (drug effects)
• Cell Differentiation (drug effects)
• Cell Growth Processes (drug effects)
• Cell Line, Tumor
• Down-Regulation
• Humans
• Neuroblastoma (drug therapy, pathology)